SAN FRANCISCO, Nov. 12 VIA Pharmaceuticals(Nasdaq: VIAP), a biotechnology company focused on the development ofcompounds for the treatment of cardiovascular disease, today announced theexpansion of its clinical advisory board. Joining the clinical advisoryboard's chair, Marc Pfeffer, M.D., Ph.D., Dzau Professor of Medicine, HarvardMedical School, and Senior Physician, Brigham & Women's Hospital in Boston,and Jean-Claude Tardif, M.D., Associate Professor of Medicine, University ofMontreal, and Director of Research, Montreal Heart Institute, are Marcelo DiCarli, M.D., Associate Professor of Radiology, and Chief of Nuclear Medicine,Brigham and Women's Hospital; Robert Fenichel, M.D., Ph.D, Former DeputyDivision Director, Division of CardioRenal Drug Products, Food and DrugAdministration; Peter Libby, M.D., Mallinckrodt Professor of Medicine, andChief, Cardiovascular Division, Brigham and Women's Hospital; and, Jean-LucienRouleau, M.D., Dean, Faculty of Medicine, University of Montreal.
"The addition of these well-respected physicians to VIA's clinicaladvisory board comes at an important time in our history," said Larry Cohen,Ph.D., president and chief executive officer of VIA. "As we prepare for therelease of Phase II clinical trial data in the middle of 2008, our clinicaladvisory board will provide independent medical, scientific, and regulatoryguidance in supporting our efforts to advance VIA-2291 as a treatment ofcardiovascular disease."
VIA's lead product candidate, VIA-2291, is a small molecule drug thattargets inflammation in the blood vessel wall, a primary disease process inatherosclerosis. VIA-2291 is a potent, selective and reversible inhibitor of5-LO, which is a key enzyme in the biosynthesis of leukotrienes (importantmediators of inflammation involved in the development and progression ofatherosclerosis). VIA-2291 is being developed as a once-daily, oral drug totarget inflammation in the blood vessel wall, thereby potentially decreasingthe risk of major adverse cardiovascular events, including heart attack andstroke. According to the American Heart Association, 15.8 million patients inthe U.S. have coronary artery disease.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on thedevelopment of compounds for the treatment of cardiovascular disease. VIA isbuilding a pipeline of small-molecule drugs that target a significant unmetmedical need: reducing inflammation in the blood vessel wall, which is anunderlying cause of atherosclerosis and its complications, including heartattack and stroke. The company's lead drug candidate, VIA-2291, is in multiplePhase II clinical studies in patients with cardiovascular disease. For moreinformation, visit: http://www.viapharmaceuticals.com.
This press release may contain "forward-looking" statements within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements relate to future events or to VIA's future financial performanceand involve known and unknown risks, uncertainties and other factors that maycause VIA's actual results, levels of activity, performance or achievements tobe expressed or implied by these forward-looking statements. In some cases,you can identify forward-looking statements by the use of words such as "may,""could," "expect," "intend," "plan," "seek," "anticipate," "believe,""estimate," "predict," "potential," "continue" or the negative of these termsor other comparable terminology. You should not place undue reliance onforward-looking statements since they involve known and unknown risks,uncertainties and other factors which are, in some cases, beyond VIA's controland which could materially affect actual results, levels of activity,performance or achievements.
Factors that may cause actual results to differ materially from curr